Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (571-580 of 842) with videos related to

Pageof 85
Sort By:
Journal of Thrombosis and Thrombolysis|August 6, 2005
The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS)David B Matchar, Alan K Jacobson, Robert G Edson, et al.
European Journal of Heart Failure|March 7, 2024
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trialJustin Ezekowitz, Wendimagegn Alemayehu, Frank Edelmann, et al.
European Heart Journal|October 26, 2017
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk scoreZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
Journal of the American Heart Association|November 8, 2021
Blood Pressure and Safety Events With Vericiguat in the VICTORIA TrialCarolyn S P Lam, Hillary Mulder, Yuri Lopatin, et al.
Journal of Cardiac Failure|April 22, 2004
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristicsBarry M Massie, William F Krol, Susan E Ammon, et al.
Circulation|March 18, 2009
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trialBarry M Massie, Joseph F Collins, Susan E Ammon, et al.
American Heart Journal|September 29, 2014
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Emily C O'Brien, DaJuanicia N Simon, Larry A Allen, et al.
Circulation|June 7, 2018
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial FibrillationAbhinav Sharma, Ziad Hijazi, Ulrika Andersson, et al.
Circulation. Cardiovascular Quality and Outcomes|August 1, 2013
Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF)Jonathan G Howlett, Justin A Ezekowitz, Mohua Podder, et al.
Lancet (London, England)|April 9, 2016
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation studyZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
Pageof 85

Showing results (571-580 of 842) with videos related to

Sort By:
Pageof 85
Journal of Thrombosis and Thrombolysis|August 6, 2005
The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS)David B Matchar, Alan K Jacobson, Robert G Edson, et al.
European Journal of Heart Failure|March 7, 2024
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trialJustin Ezekowitz, Wendimagegn Alemayehu, Frank Edelmann, et al.
European Heart Journal|October 26, 2017
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk scoreZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
Journal of the American Heart Association|November 8, 2021
Blood Pressure and Safety Events With Vericiguat in the VICTORIA TrialCarolyn S P Lam, Hillary Mulder, Yuri Lopatin, et al.
Journal of Cardiac Failure|April 22, 2004
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristicsBarry M Massie, William F Krol, Susan E Ammon, et al.
Circulation|March 18, 2009
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trialBarry M Massie, Joseph F Collins, Susan E Ammon, et al.
American Heart Journal|September 29, 2014
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Emily C O'Brien, DaJuanicia N Simon, Larry A Allen, et al.
Circulation|June 7, 2018
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial FibrillationAbhinav Sharma, Ziad Hijazi, Ulrika Andersson, et al.
Circulation. Cardiovascular Quality and Outcomes|August 1, 2013
Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF)Jonathan G Howlett, Justin A Ezekowitz, Mohua Podder, et al.
Lancet (London, England)|April 9, 2016
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation studyZiad Hijazi, Jonas Oldgren, Johan Lindbäck, et al.
Pageof 85